Effect of convalescent plasma therapy on treatment of 3 non-Hodgkin lymphoma patients complicated with COVID-19 after chemotherapy
OBJECTIVE To evaluate the effectiveness of convalescent plasma therapy in treatment of the non-Hodgkin lymphoma(NHL)patients with COVID-19 after rituximab chemotherapy.METHODS The clinical data were collected from 3 NHL patients who received convalescent plasma therapy and had COVID-19 after rituximab chemotherapy in fever clinic of the First Medical Center of Chinese PLA General Hospital from Feb 1,2023 to Feb 28,2023.The gender,age,underlying diseases,time interval between onset and blood transfusion,time interval between onset and SARS-CoV-2 nucleic acid turning to be negative,treatment time,number of times of blood transfusion and blood transfusion volume were recorded;the results of laboratory tests for white blood cell(WBC)counts,C-reactive protein(CRP)and interleukin-6(IL-6)as well as the lung imaging findings were observed.RESULTS Among the 3 patients,2 patients were male,and 1 patient was female;they were 53 years old,55 years old and 60 years old,respectively;the 3 patients were respectively with SARS-CoV-2 nucleic acid tested positive at the ad-mission to the hospital,CO VID-19 antibody tested negative,and clear pulmonary infection.The 3 patients were respec-tively given intravenous infusion of convalescent plasma for 14 times(6 640 ml in total),10 times(4 340ml in total)and 2 times(780 ml in total)on basis of the standard treatment after the admission for 3 days.The SARS-CoV-2 nucleic acid was tested negative after the convalescent plasma therapy for 14,4 and 2 days;the body temperature gradually returned to normal range after the nucleic acid was tested negative,the levels of WBC,CRP and IL-6 rose gradually after the infu-sion of plasma and gradually declined to normal ranges after the SARS-CoV-2 nucleic acid turned to be negative.The CT image of the lungs indicated that the pneumonia was absorbed obviously.The 3 patients were respectively discharged after they were hospitalized for treatment for 30,15 and 16 days,and a 3-month follow-up showed that there was no case of recurrence.CONCLUSION The convalescent plasma therapy combined with the standard therapy may achieve posi-tive effect on the rehabilitation of the NHL patients who have COVID-19 after rituximab chemotherapy,which provide more options for the clinical treatment.
Non-Hodgkin lymphomaRituximabCOVID-19Convalescent plasma of COVID-19 patientCurative effect
NETL
NSTL
万方数据
维普
